MX358050B - Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. - Google Patents

Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.

Info

Publication number
MX358050B
MX358050B MX2013005016A MX2013005016A MX358050B MX 358050 B MX358050 B MX 358050B MX 2013005016 A MX2013005016 A MX 2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A MX 358050 B MX358050 B MX 358050B
Authority
MX
Mexico
Prior art keywords
nucleic acid
methods
compositions
nanopolymer
acid delivery
Prior art date
Application number
MX2013005016A
Other languages
English (en)
Spanish (es)
Other versions
MX2013005016A (es
Inventor
N Vournakis John
V Demcheva Marina
Original Assignee
Marine Polymer Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marine Polymer Tech Inc filed Critical Marine Polymer Tech Inc
Publication of MX2013005016A publication Critical patent/MX2013005016A/es
Publication of MX358050B publication Critical patent/MX358050B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MX2013005016A 2010-11-06 2011-11-07 Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. MX358050B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US41135810P 2010-11-08 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Publications (2)

Publication Number Publication Date
MX2013005016A MX2013005016A (es) 2014-03-12
MX358050B true MX358050B (es) 2018-08-03

Family

ID=46025153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005016A MX358050B (es) 2010-11-06 2011-11-07 Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2011323078B2 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用dnaワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) * 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Also Published As

Publication number Publication date
AU2016201640A1 (en) 2016-04-07
ES2763432T3 (es) 2020-05-28
AU2011323078B2 (en) 2016-04-14
CN108743562A (zh) 2018-11-06
AU2011323078A1 (en) 2013-05-02
WO2012061803A3 (en) 2012-08-16
EP2635261A2 (en) 2013-09-11
US20170128382A1 (en) 2017-05-11
US20130287853A1 (en) 2013-10-31
IL226170A0 (en) 2013-07-31
US20230157971A1 (en) 2023-05-25
CA2816999A1 (en) 2012-05-10
EP2635261A4 (en) 2014-09-17
JP2016164181A (ja) 2016-09-08
AU2013203247A1 (en) 2013-05-09
MX2013005016A (es) 2014-03-12
JP6029591B2 (ja) 2016-11-24
JP2014500250A (ja) 2014-01-09
CN103282024A (zh) 2013-09-04
EP2635261B1 (en) 2019-10-23
IL226170B (en) 2018-11-29
WO2012061803A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
MX358050B (es) Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
MX342439B (es) Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos.
NZ604063A (en) Compositions and methods for enhancing physiological performance and recovery time
EP4393549A3 (en) Compositions for the delivery of trna as nanoparticles and methods of use therewith
WO2014004993A3 (en) Methods of reducing ldl-p
PH12015500407A1 (en) Methods of treating hypertriglyceridemia
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
MX345404B (es) Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol- 2-il]-1h-quinolin-2-ona.
WO2013041975A3 (en) Pyrethroid formulations
IL227623B (en) Preparations of extremely tiny particles containing a population of particles, for use in creating a medicine for topical treatment in patients who suffer or tend to suffer from a disease related to the sweat glands and/or the mammary glands
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
GB201121288D0 (en) Functionalised silicon nanoparticles
WO2011069010A3 (en) Amantadine compositions and methods of use
BR112014014832A8 (pt) formulação e método de controlar fungos
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
WO2011129588A3 (ko) 경피흡수용 고분자-리포좀 나노복합체 조성물 및 그 제조방법
WO2012040331A3 (en) Multistage nanoparticles
JP2014500250A5 (enExample)
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
SG195192A1 (en) Non-peptidyl polymer-insulin multimer and method for producing the same
NZ725969A (en) Compositions and method for nanopolymer-based nucleic acid delivery

Legal Events

Date Code Title Description
FG Grant or registration